Biotech Co. Must Face Securities Suit Over FDA Rejection
By Rachel O'Brien ( July 22, 2020, 4:56 PM EDT) -- A New York federal judge on Tuesday rejected a bid from Acer Therapeutics to reverse his decision to allow a proposed securities class action to continue as it alleges the biotech company misrepresented conversations with the U.S. Food and Drug Administration and hurt investors after the FDA rejected a new drug application....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.